Sapiens · Weight · GLP-1

GLP-1 side effects: what’s common, what’s serious, and when to get help

Reviewed by · Published: August 19th, 2026 · ~19 min read
Indian woman at a laptop looking uncomfortable and holding her stomach — visualizing GLP-1 side effects like nausea and stomach pain.
A weekly injection is a weekday routine long before it is anything else. This article covers what that routine feels like, and the small number of symptoms that mean stopping it.

The class-wide picture. Different incretin medicines, a strongly overlapping side-effect pattern: what the trials counted, what the safety regulators concluded, and what changes now that generics have reached India.

GLP-1 side effects are mostly gut side effects, they cluster in the first weeks and after every dose increase, and they settle for most people who get through the climb. In the 68-week obesity trial of semaglutide 2.4 mg, 74.2% of participants reported at least one gastrointestinal event, against 47.9% on placebo.1 Read the placebo figure twice, because it decides how you should read the first one. Around one in twenty people stopped treatment because of gut symptoms. A much smaller group runs into something serious, and the serious list is short enough to memorise: severe abdominal pain, right-sided pain with fever or jaundice, vomiting you cannot stop, a swollen silent abdomen, sudden vision loss.

This page covers the class as a whole, which now runs from weekly injections to daily tablets and, in India since March 2026, from originator brands to dozens of Indian generics. If you are on one particular medicine and want its own numbers, prices and quirks, those live on their own pages: Ozempic side effects, Ozempic in India, Mounjaro in India and Wegovy in India.

GLP-1 side effects at a glance Copy link

Rates below are from the pooled STEP 1–3 trials of semaglutide 2.4 mg over 68 weeks. Tirzepatide's rates sit in the same range at comparable doses.2,5

Common effects, measured rates, and what each one usually calls for
EffectHow commonWhat it usually calls for
Nausea43.9% vs 16.1% on placeboSmaller meals, less fat, slower dose climb. Tell your prescriber if it is persistent, worsening, or limiting food or fluid intake
Diarrhoea29.7% vs 15.9%Keep fluids up. Seek advice if persistent, severe, or accompanied by dizziness or reduced intake
Vomiting24.5% vs 6.3%Watch hydration closely. Review if you cannot keep fluids down
Constipation24.2% vs 11.1%Fluid, fibre, walking; a laxative if your doctor agrees
Reduced appetite, early fullnessCommon, and intendedProtein first at every meal
Hair shedding3% vs 1% in the semaglutide 2.4 mg trials13Usually starts 2–4 months in and recovers. Check ferritin, TSH, vitamin D
Severe upper-abdominal pain going through to the backUncommonStop and seek assessment the same day
Right-upper-abdominal pain with fever, chills or yellowing eyesUncommonUrgent assessment
Sudden vision loss in one eyeVery rare, semaglutideUrgent medical and eye assessment

What is a GLP-1 agonist, and which ones exist in India? Copy link

GLP-1 stands for glucagon-like peptide-1, a hormone your small intestine releases within minutes of eating. It prompts insulin when glucose is high, quiets glucagon, slows the stomach, and tells the brain you have had enough. The natural hormone lasts about two minutes in the blood. A GLP-1 receptor agonist is a molecule built to press the same receptor while resisting that breakdown, so one dose works for a day or a week.

The class as you would meet it in an Indian pharmacy, August 2026
MoleculeBrands you may be handedHow it is taken
SemaglutideOzempic, Wegovy, Rybelsus, and generic brands since March 2026Weekly injection; Rybelsus and its generics are daily tablets
TirzepatideMounjaro; YurpeakWeekly injection
DulaglutideTrulicityWeekly injection
LiraglutideVictoza, Saxenda and genericsDaily injection
ExenatideOlder brands, now little usedDaily or weekly injection

One piece of precision about tirzepatide, since it changes what you can safely assume. Tirzepatide activates a second incretin receptor, GIP, alongside GLP-1, which makes it a dual agonist and not a pure GLP-1 one. Clinicians and drug regulators still discuss it with the class because the overlap in use and in side-effect pattern is close. Where its numbers diverge, this page says so.

A choice you may already have made without noticing: injection or tablet. The GLP-1 medicines available in India guide maps what each one costs, and the generic semaglutide brands page covers the post-patent landscape.

Why does one medicine cause so many different effects? Copy link

Because GLP-1 receptors sit in several tissues at once, and nothing lets the medicine press one without pressing the others. The signal that produces the weight loss produces the symptom list.

Why one GLP-1 signal produces the whole side-effect list Cajal-style flow figure: a central GLP-1 receptor motif sends four inked arrows to organic nodes representing brain appetite centres, stomach emptying, gallbladder emptying and gut transit, each keyed to the side effect it produces. PLATE 31 · WEIGHT & METABOLIC SAPIENS ATLAS One signal, four destinations glp-1 agonist side effects · mechanism of action · receptor signalling GLP-1 RECEPTOR 01 02 03 04 a — brain appetite centres + brainstem: fullness, early nausea b — stomach emptying slows: nausea, bloating, reflux c — gallbladder empties less; rapid loss favours stones d — gut transit slows: constipation FIG. 1 · ONE RECEPTOR, FOUR EFFECTS · INK & JEWEL WASH · AFTER CAJAL · DRAWN 19 AUG 2026
One signal, four destinations. The receptor is reached in the brain, the stomach, the gallbladder and the gut, and each stop explains one cluster of effects. Tirzepatide additionally activates the GIP receptor, which this figure does not show.

Follow the four arrows. In the brain, appetite centres and the brainstem produce fullness, which is the intended effect, and early nausea, which is not. In the stomach, emptying slows, so food sits longer, and that is why you push a plate away six bites in and also why the sitting food can mean nausea, bloating and reflux. In the gallbladder, contraction weakens while rapid weight loss thickens bile, a pairing that favours stones. In the gut, transit slows, and you feel that as constipation.

Nothing on that list is a mysterious reaction to a foreign chemical. Each one is the mechanism, felt from the inside. Dose and escalation speed strongly influence how any of this feels, though the molecule and the individual patient matter too.

How common are the common ones, really? Copy link

The most detailed count for the class comes from the pooled STEP 1–3 trials, which followed participants on semaglutide 2.4 mg for 68 weeks and logged every complaint.2

GLP-1 agonist side effects: the measured trial rates Paired horizontal bars compare semaglutide 2.4 mg with placebo for nausea, diarrhoea, vomiting and constipation over 68 weeks in the pooled STEP 1-3 trials; a footnote records that 4.3% versus 0.7% stopped treatment because of gut effects. PLATE 31 · FIG. 2 · WEIGHT & METABOLIC SAPIENS ATLAS What the trials actually counted semaglutide 2.4 mg vs placebo · pooled STEP 1–3 trials · 68 weeks SEMAGLUTIDE 2.4 MG PLACEBO 01020304050% OF PARTICIPANTS · 68 WEEKSNauseadrug · placebo43.9%16.1%Diarrhoeadrug · placebo29.7%15.9%Vomitingdrug · placebo24.5%6.3%Constipationdrug · placebo24.2%11.1% STOPPED TREATMENT FOR GUT EFFECTS: 4.3% VS 0.7% · 98.1% OF EVENTS MILD–MODERATE FIG. 2 · WHARTON ET AL., DIABETES OBES METAB 2022 · INK & LAPIS WASH · DRAWN 19 AUG 2026
What the trials actually counted. Gastrointestinal event rates over 68 weeks, semaglutide 2.4 mg against placebo, pooled from STEP 1 to STEP 3.

Three details from that dataset deserve as much attention as the bars. 98.1% of the gut events were graded mild or moderate and 99.5% were non-serious. New events clustered during dose escalation and the curve flattened after about week 20, so the climb is the hard part and the plateau is not. And look again at the placebo column: nearly half of people on a dummy injection reported gut symptoms, because bloating, loose stools and nausea are ordinary features of adult life. The medicine's added burden is the gap between the columns, and the gap is smaller than the first column alone suggests.

Tirzepatide's ledger reads similarly. Pooling ten randomised trials covering 6,836 participants put any gastrointestinal event at 39%, 46% and 49% for the 5, 10 and 15 mg doses.5 That dose-dependence is the pattern to carry across the whole class. In SURMOUNT-1, the proportion stopping for adverse events ran 4.3% at 5 mg, 7.1% at 10 mg and 6.2% at 15 mg, against 2.6% on placebo.3 So somewhere between one person in twenty and one in fourteen stops because of side effects, depending on dose, and the rest carry on.

A second tier of effects sits below the headline four. Burping, often sulphurous, and reflux both follow the slowed stomach. Fatigue and mild dizziness turn up early and usually track how little you are suddenly eating and drinking. A small rise in resting heart rate, a few beats a minute, is documented across the class labels, and injection sites can be briefly red or itchy.13 None of these ordinarily needs treatment. What they need is what the nausea needs: fluids, patience through each dose step, and a prescriber who knows they are happening.

Do side effects mean the medicine is working? Copy link

No, and the trial data on this are unusually direct. In the pooled STEP analysis, participants who had gut side effects lost 11.4% to 17.7% of body weight; those who had none lost 9.6% to 17.1%. The investigators then asked how much of the drug's weight loss actually travelled through the gut symptoms, and the answer came back under one percentage point of the total.2

Sit with what that means in both directions. If your first month is rough, the nausea buys you nothing, and enduring severe symptoms in silence is a poor trade when a slower climb reaches the same place in more comfort. And if you sail through with nothing at all, nothing is wrong with you or with the medicine. Appetite suppression is doing the work either way, mostly in the brain, and it does that work silently.

How can you reduce the common side effects? Copy link

Most of what helps is unglamorous, and most of it works by respecting a stomach that is now emptying slowly. None of it substitutes for telling your prescriber what is happening.

Go up slowly, and treat the schedule as negotiable. Dose escalation is where the trouble concentrates, in every trial that has looked. If a step is rough, the usual answer is to hold at the current dose for longer before climbing, which is one of the most useful tolerability tools a prescriber has, and the decision belongs with them. A dose you tolerate and can stay on beats a higher one you abandon in month three.

Eat smaller, earlier, and less rich. Smaller portions more often, stopping at the first sign of fullness, and going easy on fried and high-fat food, which slows an already slow stomach further. Many people find bland and simple works during a bad week: khichdi, curd rice, dal, toast, idli. Try not to lie down straight after eating if reflux is the problem.

Protect fluid and protein first. Appetite falls, so what you do eat has to carry more. Protein at every meal, and steady fluid across the day instead of a litre at once. Consider keeping an eye on how much you are actually drinking during a vomiting or diarrhoea week, since dehydration is the route by which an ordinary side effect turns into a hospital visit.

For constipation, move before you medicate. Fluid, fibre and a daily walk handle most of it. If it persists despite those, ask your clinician or pharmacist which treatment suits you. Constipation with significant pain, vomiting, abdominal swelling, or no stool or wind passing needs assessment and not self-treatment.

Time the injection to your week. Symptoms often peak in the day or two after the dose. Many people shift the injection so those days land where they cost least. Ask before changing the day, since there are rules about how far a dose can move.

What is not a home remedy: severe pain, unstoppable vomiting, a swollen abdomen, or vision changes. Those belong in the list further down, and none of them should be managed with dose adjustments you make yourself.

Which side effects are actually serious? Copy link

Four deserve naming plainly, with their measured sizes.

Gallbladder disease. Pooling 76 randomised trials with 103,371 participants, GLP-1 agonist use raised the relative risk of gallbladder or biliary disease by 37%.6 Two caveats belong in the main text and not in a footnote: the absolute increase was about 27 extra cases per 10,000 people per year, and gallbladder events were not a predefined outcome in most included trials, so some under-reporting is likely. Risk ran higher at higher doses, with longer use, and in the weight-loss trials specifically, where the relative risk reached 2.29. New, persistent pain under the right ribs on treatment should be assessed promptly. Severe pain, fever, chills or yellowing of the eyes needs urgent assessment, because that combination can mean an inflamed or obstructed gallbladder rather than a passing ache.

Pancreatitis. Severe upper-abdominal pain that will not ease and drills backwards into your mid-back, with or without vomiting, means stopping the medicine and being seen the same day. For scale: in the tirzepatide pooling above, pancreatitis occurred in 1% of participants or fewer at every dose, and the large outcome trials of the class have not shown a clear excess.5

A stalled or blocked bowel. In September 2023 the US FDA added ileus to semaglutide's label on the strength of voluntary post-marketing reports. The label states plainly that because those reports come from a population of unknown size, frequency and causation cannot be established.13 It is the far end of the same slowed-motility mechanism you met in Fig. 1, which is why persistent vomiting with a swollen, silent abdomen is an emergency and never something to wait out.

Dehydration and the kidneys. The kidney injuries reported with these medicines mostly follow one script: vomiting and diarrhoea, too little fluid replaced, and an acute kidney injury on top. This is not the same as direct kidney toxicity. Semaglutide has shown kidney-protective outcome benefits in people with type 2 diabetes and chronic kidney disease, and carries a US indication on that basis since January 2025; the acute kidney injury warning sitting alongside it is largely about volume depletion, when vomiting or diarrhoea takes out more fluid than a person replaces.13 Separately, low blood sugar is uncommon on a GLP-1 agonist alone, becoming a real risk mainly alongside insulin or a sulfonylurea, which is why doctors often cut those doses when starting one.

What have the safety reviews actually concluded? Copy link

Over three years this class has been through more formal scrutiny than almost anything else on the market. The verdicts, in order, are the part worth knowing.

Four safety questions and where each one landed
ConcernWho reviewed itWhat was concluded
Thyroid C-cell tumoursUS boxed warning, from rodent studiesA rodent finding whose relevance to humans has not been established. The class is still avoided by anyone whose family or own history includes medullary thyroid cancer or MEN2.13
Surgery and anaesthesiaAmerican Society of Anesthesiologists, 2023; multi-society update, 2024The 2023 guidance suggested holding a weekly dose before elective procedures. The 2024 update moved to individual risk assessment, with most people able to continue. The constant: tell your surgical and anaesthetic team you take one.15
Suicidal thoughts and behaviourEMA safety committee, April 2024; FDA final review, January 2026The FDA completed its review across 91 placebo-controlled trials covering 107,910 participants, found no increased risk, and requested removal of the warning from the weight-management labels. The European review had already concluded in 2024 that the evidence did not support a causal link.7,8
NAION, a rare optic-nerve strokeEMA safety committee, June 2025; WHO advisory committee, 2025Classified a very rare side effect of semaglutide, a frequency category meaning up to 1 in 10,000 users. Observational studies suggest roughly a doubling of an uncommon baseline risk, while trial-level analyses have not found a significant increase, so the true size is unsettled. Sudden vision loss means calling your doctor without delay, and semaglutide is stopped if NAION is confirmed.9,10,11

Two things about NAION are worth stating precisely, because precision is the whole value of that row. The signal rests on semaglutide data; whether it extends across the class has not been determined.10 And the estimates diverge by study design. A meta-analysis of observational studies in type 2 diabetes put the increase at roughly two-fold, working out to about one extra case per 7,000 people treated for a year, at the higher end of the published estimates; a large US claims analysis found no increased risk at all in the first six months, with an incidence difference of 3 cases per 100,000 users and a confidence interval crossing zero.11,12 Both can be true of a condition this rare, and neither changes what you should do: sudden vision loss gets seen urgently.

Notice the shape of the table as a whole. The item that sounds most frightening rests on rodent data and an unresolved question, while the ones that actually send people to hospital are the mundane abdominal problems in the section above.

Muscle loss and hair shedding Copy link

Both are real, and both are bound up with how fast the weight comes off. That does not make either one purely a consequence of weight loss, and it is worth being careful about which parts are measured and which are inferred.

Start with what was measured. In the STEP 1 body-composition substudy, 140 participants had DXA scans at the start and at 68 weeks. On semaglutide 2.4 mg, total fat mass fell 19.3% and total lean mass fell 9.7%, while lean tissue rose as a proportion of body weight, because fat fell faster.1 Some lean-mass loss is expected during substantial weight reduction, and the proportion reported varies considerably across studies, medicines and measurement methods. Because the percentage changes in fat mass, lean mass and total weight each use a different denominator, converting them into a single tidy fraction is easy to get wrong, so the measured compartment changes are given here and left as they are.

Why it matters more here. At any given BMI, South Asians tend to carry more fat and less skeletal muscle than Europeans, the pattern Indian endocrinology literature calls the thin-fat phenotype, and it travels with a high background rate of sarcopenic obesity.20 Baseline protein intake compounds it: the ICMR-NIN 2020 requirement for a healthy Indian adult is 0.83 g per kg of body weight a day, and habitual intake often sits near 0.6 g/kg of reference body weight.19,20 Indian consensus work on sarcopenia makes the same point from the muscle side: lower muscle mass, higher adiposity, and cereal-based diets lower in protein quality.21 Losing weight quickly from that starting point is a different proposition from doing it on a Western diet.

What protects it. Pooling randomised trials of intentional weight loss in adults with overweight or obesity, higher protein intake significantly slowed the loss of lean mass, and the authors put the supported minimum at about 1.3 g per kg per day, which is where the 1.2 to 1.6 g/kg range used in obesity practice comes from.18 Indian nutrition literature lands in the same place for adults with chronic disease, at 1.2 to 1.5 g/kg, with an explicit exception for chronic kidney disease on conservative management.21 Two things to settle with your own doctor before you use any of those numbers. Which body weight the target is calculated from, since actual, adjusted and ideal body weight give very different answers in obesity. And whether your kidney function allows it, because a population figure is not a personal one. Protein without resistance training also does much less than either does with the other.

On hair. Increased shedding typically shows up two to four months after rapid loss begins, comes out diffusely in the shower and on the pillow, and recovers as weight and nutrition steady, which is the pattern of telogen effluvium. The semaglutide 2.4 mg trials recorded hair loss in about 3% of participants against 1% on placebo, described in the label as associated with weight reduction, and the tirzepatide obesity trial recorded roughly 5% against 0.9%.3,13 A 2026 systematic review reported a dose relationship for alopecia across this class, and a real-world study of two propensity-matched cohorts of 547,993 adults each found higher adjusted odds of telogen effluvium at twelve months (aOR 1.76), though not at six.16,17 Rapid weight loss and reduced intake probably explain much of it. The evidence does not yet justify saying every case is only that, so if your shedding is heavy or is not settling by month six, get it looked at instead of waiting it out. Checking ferritin, TSH and vitamin D is worth doing early, since a hidden deficiency will make any shed worse.

What changes in India now that generics are here? Copy link

Semaglutide's Indian patent expired on 20 March 2026. More than forty companies had prepared over fifty brands for the window, and launches began within a day.30 The category was already climbing steeply: injectable GLP-1 sales rose 218% on a moving annual basis to ₹1,736 crore in April 2026, from ₹545 crore in April 2025.26 Access stopped being the constraint. Supervision became the entire question, in a country whose own expert consensus now defines obesity at lower thresholds than the international ones, which puts more people inside the conversation to begin with.22

There is a licensing detail underneath all of this that rarely reaches the pharmacy counter, and it is the most useful thing on this page for an Indian reader. Approval in India is per product and per indication, and not simply per molecule. Wegovy is the semaglutide brand built around chronic weight management, while Ozempic is licensed for type 2 diabetes.13,14,26 Among the generics, individual products may carry diabetes, obesity, or both, depending on what each one was approved for: Dr Reddy’s Obeda, the first DCGI-approved generic semaglutide, launched with a type 2 diabetes indication and weight-management expansion pending.28 Tirzepatide sits differently again. Mounjaro, and Yurpeak, a second Lilly tirzepatide brand distributed and promoted by Cipla, are marketed in India across both type 2 diabetes and chronic weight management.27 So some weight-loss prescribing here sits outside the particular product’s approved indication even though the molecule is licensed for weight management in another brand. That is legitimate clinical practice with a doctor’s judgement behind it. It is also a reason to ask which indication your prescription sits under, because it shapes what your prescriber is monitoring and what a pharmacist is permitted to dispense. Check the approved indication of the exact product being prescribed instead of assuming from the molecule.

The regulator has been moving in the same window. On 10 March 2026 the CDSCO advised manufacturers and marketing authorisation holders against surrogate advertising and indirect promotion of these prescription medicines, including disease-awareness campaigns and influencer content built for brand recall.24 By 24 March, 49 entities including online pharmacy warehouses, wholesalers, retailers and slimming clinics had been inspected, and on 27 March all state and union territory drug controllers were asked to strengthen monitoring across the supply chain.25 In May 2026 they were asked to actively monitor print, broadcast, digital, social and outdoor media for surrogate promotion, with action available under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.26

One rule from that same push is worth knowing before you book anything. The government’s own explainer states that in India these medicines may be prescribed only by endocrinologists, internal medicine specialists and cardiologists, and cannot be bought over the counter.25 The Drugs Consultative Committee took the matter up at its 68th meeting and asked state and union territory controllers to keep a vigil on approved indications, labelling, ethical marketing and risk-management obligations, and asked the Indian Pharmacopoeia Commission to compile a monthly or bi-monthly review of adverse events for these medicines.24 Whoever writes your prescription should fit that description, and should be someone you can reach again when a dose step goes badly.

None of that is bureaucratic noise from your side of the counter. A seller who ships a pen without a prescription is also telling you that nobody will be watching your dose escalation, your fluid intake, or the warning signs above. The WHO reached the same conclusion from the other direction: its first guideline on these medicines, published in December 2025, conditionally supports long-term use in adults with obesity and states that it should sit inside a chronic-care model with personalised, periodic monitoring of response and adverse events.23 Supervision is not an upsell. It is the condition under which the evidence applies.

Baseline and follow-up bloods are the practical shape that monitoring takes: HbA1c and a lipid profile are the two most people start with. If you are still deciding whether treatment fits you at all, that question belongs on the weight-loss treatment in India pillar rather than here.

Do GLP-1 tablets have the same side effects as injections? Copy link

Broadly yes, because the receptor does not care how the molecule arrived. Oral semaglutide produces the same family of effects, worst around dose increases, and the tablets available in India now include generic versions as well as the originator: Torrent launched Semalix, the first Indian generic oral semaglutide, on 21 March 2026, alongside its injectable brand.29

The practical differences sit in absorption, and not in tolerability. Oral semaglutide must be taken on an empty stomach with a small sip of water, at least 30 minutes before any other food, drink or medicine, because food destroys its already low uptake. Miss that rule and you mostly lose the dose while keeping the side effects. Higher oral doses, as you would expect from a dose-dependent class, have carried higher rates of some effects: in weight-loss trials of 50 mg oral semaglutide, hair loss was reported by 7% of participants against 3% of controls.16

Two developments abroad are worth knowing, because they will shape what reaches India next. The US approved an oral semaglutide tablet for weight management in December 2025, and in April 2026 approved orforglipron, the first once-daily small-molecule GLP-1 tablet, which carries no food or water restriction.31 Neither is licensed in India as of August 2026. Expect the class effects to travel with them when they arrive, because the receptor is the same.

Who needs extra caution before starting? Copy link

A short list your prescriber will work through, worth previewing so none of it is a surprise.

Medullary thyroid cancer in you or in a close relative, or MEN2, keeps you off the class. A previous episode of pancreatitis calls for a genuine conversation about risk, as does known gallstone disease. If you have diabetic retinopathy, note that rapid glucose correction with semaglutide was linked to early worsening of retinopathy in one large diabetes trial, so a retinal check before starting is sensible. Severe gastroparesis and other active gut disease need individual judgement, for reasons Fig. 1 makes obvious.

Pregnancy is different from the rest, and so is breastfeeding, which often gets folded into it incorrectly. Weight-management treatment with this class is not for use in pregnancy, and a planned pregnancy needs a molecule-specific stopping window agreed in advance, because half-lives differ. Breastfeeding advice is set per product and not per class: some formulations advise against it outright, others weigh maternal need against the possible risk to the infant. Check your own product's prescribing information with your doctor instead of assuming a single class-wide rule.

When should you stop and call a doctor? Copy link

Keep the ordinary symptoms in proportion, and treat this list as non-negotiable. Severe upper-abdominal pain drilling backwards into the mid-back, with or without vomiting. Right-sided upper-belly pain with fever, chills or yellowing eyes. Vomiting that will not stop, or a day when you cannot hold fluids down. A swollen, painful abdomen with no wind or stool passing. Sudden loss or blurring of vision in one eye. Swelling of the face or throat, or difficulty breathing. And shakiness, sweating or confusion if you also take insulin or a sulfonylurea.

Everything there is uncommon. Everything there is also time-sensitive, which is why it is worth knowing by heart instead of bookmarking. Dose changes belong with your doctor in every case, including the tempting one where you feel fine and want to climb faster.

Frequently asked questions Copy link

What is a GLP-1 agonist in simple terms?

A prescription medicine that copies GLP-1, a gut hormone released after meals. It prompts insulin when blood sugar is high, slows stomach emptying and reduces appetite, which is why the class treats both type 2 diabetes and obesity. Semaglutide, tirzepatide, dulaglutide and liraglutide are the main members; tirzepatide also acts on a second incretin receptor, GIP.

What are the most common GLP-1 side effects?

Gut effects. In the pooled STEP trials of semaglutide 2.4 mg, nausea affected 43.9% against 16.1% on placebo, diarrhoea 29.7% against 15.9%, vomiting 24.5% against 6.3% and constipation 24.2% against 11.1%. Reduced appetite and earlier fullness are common, and intended. Most events were mild or moderate, clustered around dose increases, and 4.3% of participants stopped treatment because of them.

How long do GLP-1 side effects last?

For most people, days to a few weeks after starting and after each dose increase. In the pooled trials, new gastrointestinal events tailed off after roughly week 20, which is around when most people have reached their maintenance dose. Symptoms that are still severe after that, or that arrive suddenly having settled, are worth reporting rather than absorbing.

Do side effects mean the medicine is working?

No. Trial participants lost almost identical weight with or without gut side effects, and a mediation analysis attributed under one percentage point of the weight loss to them. A comfortable course is not a failing one.

Which GLP-1 has the fewest side effects?

There is no universal answer, and rates cannot be compared cleanly across separate trials with different populations and definitions. Tolerability varies with the molecule, the dose, the escalation schedule and the individual. Where head-to-head data exist they are worth more than cross-trial arithmetic: in the one trial that compared them directly, discontinuation for gut effects was lower on tirzepatide (2.7%) than on semaglutide (5.6%), in an open-label trial funded by tirzepatide’s manufacturer.4 Your escalation pace is the variable you and your doctor actually control.

Do GLP-1 agonists cause thyroid cancer?

The boxed warning comes from rodent studies in which the class caused thyroid C-cell tumours. Whether that applies to humans has not been established. As a precaution, the medicines are withheld where medullary thyroid carcinoma or MEN2 appears in your own or a close relative's history, so tell your doctor if that runs in your family.

Do GLP-1 medicines cause hair loss?

Some people shed, typically two to four months after rapid weight loss begins, and it usually recovers as weight and nutrition stabilise. Hair loss was reported by about 3% of participants on semaglutide 2.4 mg against 1% on placebo, and by roughly 5% in the tirzepatide obesity trial. Rapid weight loss explains much of it; recent reviews suggest the story may not be entirely explained by weight loss alone, so persistent or heavy shedding deserves assessment rather than patience.

Are GLP-1 tablets safer than injections?

Not meaningfully. Oral semaglutide carries the same class effects and warnings. The differences are daily dosing, a strict empty-stomach rule and lower absorption. India now has generic oral semaglutide alongside the originator tablet.

Is it safe to buy GLP-1 medicines online in India?

They are Schedule H medicines and require a valid prescription, and since March 2026 the CDSCO has run inspections and issued directions specifically aimed at unauthorised sale and surrogate promotion. Beyond the legality, a seller who skips the prescription is also skipping the monitoring that catches the problems on this page early. Buy through a licensed pharmacy against a real prescription.

References Copy link

  1. Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989–1002. PMID 33567185. 1,961 adults with a BMI of 30 or above, or 27 with a weight-related condition, and without diabetes, randomised 2:1 to semaglutide 2.4 mg weekly or placebo for 68 weeks with lifestyle support. Gastrointestinal disorders occurred in 74.2% on semaglutide against 47.9% on placebo, mostly mild to moderate and transient. In the exploratory DXA substudy of 140 participants (mean weight 98.4 kg, BMI 34.8, 76% female), total fat mass fell 19.3% and total lean body mass fell 9.7% from baseline, while lean mass rose 3.0 percentage points as a proportion of body weight. The substudy drew on nine sites and excluded BMI above 40, so it illustrates body-composition change and is not a whole-trial measurement. source
  2. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight reduction. Diabetes, Obesity and Metabolism. 2022;24(1):94–105. PMID 34514682. Pooled analysis of STEP 1–3. Nausea 43.9% versus 16.1% on placebo, diarrhoea 29.7% versus 15.9%, vomiting 24.5% versus 6.3%, constipation 24.2% versus 11.1%. 98.1% of gastrointestinal events were mild or moderate and 99.5% non-serious; 4.3% discontinued for gastrointestinal reasons against 0.7% on placebo. The cumulative incidence of first events flattened after approximately week 20. Weight loss was 11.4–17.7% in participants who reported gastrointestinal events and 9.6–17.1% in those who did not, and mediation analysis attributed less than one percentage point of weight loss to those events. A pooled post-hoc analysis of trials not designed to answer this question, so it describes association and does not establish mechanism. source
  3. Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205–216. PMID 35658024. 2,539 adults with obesity, or overweight with a weight-related complication, and without diabetes, over 72 weeks. Discontinuation for adverse events was 4.3% at 5 mg, 7.1% at 10 mg and 6.2% at 15 mg, against 2.6% on placebo; the 10 mg figure is the peak and is often dropped when the range is quoted. Alopecia was reported in roughly 4.9–5.3% across dose groups against 0.9% on placebo. Participants were 70.6% White and 67.5% female with a mean baseline weight of 104.8 kg, so transfer to Indian patients is an assumption and not a finding. source
  4. Aronne LJ, Horn DB, le Roux CW, et al.; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine. 2025;393(1):26–36. PMID 40353578. 751 adults with obesity and without diabetes randomised to maximum tolerated tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) for 72 weeks: the only head-to-head comparison of the two molecules. Weight change was −20.2% with tirzepatide against −13.7% with semaglutide, and discontinuation for gastrointestinal events was lower on tirzepatide (2.7%) than semaglutide (5.6%). Open-label, so participants and investigators knew the assignment, and funded by tirzepatide's manufacturer; 76% of participants were White. source
  5. Mishra R, Raj R, Elshimy G, Zapata I, Kannan L, Majety P, Edem D, Correa R. Adverse events related to tirzepatide. Journal of the Endocrine Society. 2023;7(4):bvad016. PMID 36789109. Systematic review and meta-analysis of ten trials with 6,836 participants. Gastrointestinal events were the most common and were dose dependent: 39% (95% CI 35–43), 46% (42–49) and 49% (38–60) at 5, 10 and 15 mg. Nausea and diarrhoea were the most frequent at every dose. Fatal events, severe hypoglycaemia, acute pancreatitis, cholelithiasis and cholecystitis were all 1% or fewer at every dose. Pooling trials of differing duration, comparator and population limits how precisely these rates transfer to any one patient. source
  6. He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Internal Medicine. 2022;182(5):513–519. PMID 35344001. 76 randomised trials, 103,371 participants. Relative risk of gallbladder or biliary disease 1.37 (95% CI 1.23–1.52), an absolute increase of about 27 cases per 10,000 persons per year. Risk was higher at higher doses, with longer duration, and in weight-loss trials specifically (RR 2.29). The authors note that gallbladder events were not a prespecified outcome in most included trials, so under-ascertainment is likely and the estimate should be read as indicative. source
  7. US Food and Drug Administration. FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. Drug Safety Communication, 13 January 2026. The FDA's completed evaluation covered 91 placebo-controlled trials with 107,910 participants (60,338 on a GLP-1 medicine, 47,572 on placebo) and a Sentinel System cohort of 2,243,138 users, and identified no increased risk of suicidal ideation or behaviour. The agency requested that application holders remove the warning from Saxenda, Wegovy and Zepbound labelling. This supersedes the FDA's January 2024 preliminary communication, which found no association but could not exclude a small risk. A request to sponsors; individual product labelling is updated on its own timetable, so check the current label of the product you are prescribed. source
  8. European Medicines Agency, Pharmacovigilance Risk Assessment Committee. Meeting highlights: review of GLP-1 receptor agonists and suicidal or self-injurious thoughts concluded, 12 April 2024. The European review of Ozempic, Saxenda, Victoza, Wegovy and related products concluded that the available evidence does not support a causal association with suicidal or self-injurious thoughts and actions, and recommended no change to the product information. Regulatory conclusions rest on the data available at the time and remain subject to ongoing pharmacovigilance. source
  9. European Medicines Agency, Pharmacovigilance Risk Assessment Committee, 6 June 2025; and World Health Organization. Medical product alert: semaglutide medicines and non-arteritic anterior ischaemic optic neuropathy, 27 June 2025. PRAC concluded that NAION is a very rare side effect of semaglutide medicines, in the European frequency category meaning up to 1 in 10,000 users, and recommended a product-information update. Sudden vision loss or rapidly worsening eyesight means contacting a doctor without delay, and semaglutide is stopped if NAION is confirmed. A frequency category is a labelling convention and not a measured incidence rate. source
  10. World Health Organization Advisory Committee on the Safety of Medicinal Products (ACSoMP), May 2025 meeting conclusions on semaglutide and NAION. ACSoMP concluded that the risk management plan for semaglutide should be revised to include NAION as a potential risk, with any required additional pharmacovigilance activities. The evidence is specific to semaglutide; whether the finding extends across GLP-1 receptor agonists as a class has not been established. source
  11. Semaglutide-associated risk of non-arteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. PLOS Medicine. 2026;23:e1005064. Meta-analysis of five longitudinal observational studies, with seven more in sensitivity analysis, found semaglutide associated with an approximately two-fold increase in the hazard of NAION in type 2 diabetes, translating to roughly one additional case per 7,000 patients treated for a year. Meta-analyses of randomised trials have consistently not shown a significant increase. Observational designs cannot establish causation and are open to confounding by indication. source
  12. North American Neuro-Ophthalmology Society and American Academy of Ophthalmology. Glucagon-like peptide-1 receptor agonists and the risk of non-arteritic anterior ischemic optic neuropathy: consensus statement, 2026. The societies note that while several studies report a small possible increase in NAION risk with semaglutide, others report no correlation and the overall magnitude remains uncertain. An FDA Sentinel analysis of 134,000 matched pairs initiating semaglutide or sitagliptin found no increased risk during the first six months, with an incidence risk difference of 3 cases (95% CI 0–19) per 100,000 users. Pharmacovigilance-based studies depend on voluntary reporting and carry selection bias and under-reporting. source
  13. Ozempic (semaglutide) injection, US prescribing information. Novo Nordisk; current label including the January 2025 chronic kidney disease indication. Source for the boxed warning on thyroid C-cell tumours derived from rodent carcinogenicity studies and the contraindication in personal or family history of medullary thyroid carcinoma or MEN2; for the September 2023 addition of ileus to postmarketing experience, where the label states that because reports come from a population of uncertain size, frequency and causal relationship cannot be reliably established; for the acute kidney injury warning attributed to volume depletion from gastrointestinal losses; for the small mean rise in resting heart rate; and for the indication added in January 2025 to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial. Labelling differs between regulators, so the leaflet supplied with the product bought in India governs. source
  14. Wegovy (semaglutide) injection, US prescribing information. Novo Nordisk; current label. Source for hair loss reported in 3% of adults on semaglutide 2.4 mg against 1% on placebo across trials of 2,116 participants, and in 4% against 0% in a paediatric trial, described in the label as associated with weight reduction. Also the source for the chronic weight-management indication that distinguishes this brand from the diabetes-indicated semaglutide products, and for product-specific pregnancy and lactation language, which differs between formulations and should be read for the exact product prescribed. source
  15. American Society of Anesthesiologists consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists, June 2023; and the 2024 multi-society clinical practice guidance on periprocedural management. The 2023 guidance suggested holding weekly-dosed agonists for a week before elective procedures because of delayed gastric emptying and aspiration risk. The 2024 multi-society update moved to individualised risk assessment, with most patients able to continue and extra precautions reserved for higher-risk cases. Both are consensus documents and not trial evidence; the constant across them is disclosure of GLP-1 use to the anaesthetic team. source
  16. Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: a systematic review of current evidence and implications for counseling. Science Progress. 2026;109(1). Systematic review of alopecia associated with GLP-1 receptor agonists, reporting a dose relationship: hair loss in 7% of participants against 3% of controls in trials of 50 mg oral semaglutide for weight loss, against 3% versus 1% with subcutaneous semaglutide 2.4 mg, and little signal at the lower doses used in type 2 diabetes. Reviews of heterogeneous trial and pharmacovigilance data cannot separate a drug effect from the effect of the weight loss the drug produces. source
  17. Vidal SI, Akiska YM, Nasseri M, Menta N, Nussbaum D, Cotton CH, Castelo-Soccio L, Friedman A. Increased risk of hair loss with GLP-1 receptor agonists: a real-world multicenter TriNetX cohort study. JAAD International. 2026;25:133–135. doi:10.1016/j.jdin.2026.01.014. Two propensity-matched cohorts of 547,993 adults each, matched on age, sex, race, BMI and type 2 diabetes status, with confounding dermatologic, endocrine, nutritional and systemic conditions excluded. At 12 months, GLP-1 exposure was associated with higher adjusted odds of telogen effluvium (aOR 1.76), androgenetic alopecia (aOR 1.64) and non-scarring hair loss overall (aOR 1.40), all P < .001. At 6 months the telogen effluvium association was not significant (P = .18). Outcomes were identified from diagnostic codes, and the analysis could not adjust for the amount or speed of weight lost, which is itself an established trigger. source
  18. Kokura Y, Ueshima J, Saino Y, Maeda K. Enhanced protein intake on maintaining muscle mass, strength, and physical function in adults with overweight/obesity: a systematic review and meta-analysis. Clinical Nutrition ESPEN. 2024. doi:10.1016/j.clnesp.2024.06.030. Meta-analysis of randomised trials asking what protein intake preserves muscle during intentional weight loss in adults with overweight or obesity. Higher protein intake significantly attenuated the loss of lean mass, and the authors conclude that the evidence supports a minimum of about 1.3 g per kg per day in this group. Enhanced protein did not significantly prevent decline in muscle strength or physical function, and the trials pooled used varying body-weight denominators, which is why the denominator has to be agreed with the person prescribing. source
  19. Indian Council of Medical Research and National Institute of Nutrition. Nutrient requirements for Indians: recommended dietary allowances and estimated average requirements, 2020. The 2020 committee computed a mean requirement (EAR) of 0.66 g/kg/day and a safe protein requirement (RDA) of 0.83 g/kg/day for healthy Indian adults, revised down from 1 g/kg/day in the 2010 recommendation, with a footnote that requirements are higher for people eating cereal-based diets with lower-quality protein. A population reference for healthy adults, and not a therapeutic target during weight loss. source
  20. Kapoor N, Bhattacharya S, Agarwal N, Das S, Bantwal G, Deshmukh V, Kalra S. Subclinical kwashiorkor in adults: a new age paradigm. Indian Journal of Endocrinology and Metabolism. 2022;26(3):213–222. PMID 36248046. PubMed-indexed Indian scoping review of adult protein-energy undernutrition. Records the ICMR-NIN allowance against habitual Indian adult intake of roughly 0.6 g per kg of reference body weight, and links the South Asian thin-fat phenotype, with higher visceral adiposity at lower BMI, to sarcopenic obesity. A narrative scoping review rather than primary measurement, cited for population context and not for any individual's target. source
  21. Kalra S, Shaikh IA, Shende S, Kapoor N, Unnikrishnan AG, Sharma OP, et al. An Indian consensus on sarcopenia: epidemiology, etiology, clinical impact, screening, and therapeutic approaches. International Journal of General Medicine. 2025;18:1731–1745. PMID 40165836. Modified-Delphi consensus across Indian specialties. Notes that Indians carry lower muscle mass and higher adiposity than Western counterparts and that Indian diets are cereal-based and lower in protein quality, and recommends resistance exercise plus protein and specialised nutrients as the core intervention. Indian nutrition literature in the same area places 1.2–1.5 g/kg/day as the range for adults with chronic disease, with an explicit exception for chronic kidney disease on conservative management. Expert consensus rather than trial evidence, and framed around sarcopenia rather than around drug-induced weight loss. source
  22. Misra A, Vikram NK, Ghosh A, Ranjan P, Gulati S; India Obesity Commission. Revised definition of obesity in Asian Indians living in India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2025;19(1):102989. PMID 39814628. Delphi consensus replacing India's 2009 BMI-only definition, restaging obesity around adiposity, waist measurement and organ or functional effect rather than BMI alone. Cited here for the Indian thresholds that frame who is considered to have obesity in this country. Expert consensus rather than trial evidence; it defines obesity for diagnosis and not eligibility for any particular medicine. source
  23. Celletti F, Farrar J, De Regil L. World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults. JAMA. 2026;335(5):434–438; full guideline published 1 December 2025. PMID 41324410. WHO's first guideline on this class, developed with GRADE methodology across GLP-1 receptor agonists and GIP/GLP-1 dual agonists (liraglutide, semaglutide, tirzepatide). It conditionally recommends that these medicines may be used as long-term treatment for adults with obesity, delivered inside a chronic-care model with personalised periodic monitoring of treatment response and adverse events. The recommendation is conditional, applies to BMI of 30 or above, and states plainly that access, affordability and health-system readiness constrain implementation. WHO added GLP-1 therapies to its Essential Medicines List for high-risk type 2 diabetes in September 2025. source
  24. Central Drugs Standard Control Organisation. Minutes of the 68th meeting of the Drugs Consultative Committee, Agenda No. 10: strengthening regulatory oversight and enforcement against surrogate advertising of prescription-only medicines. The committee record confirms, from CDSCO’s own document, that an advisory dated 10 March 2026 was issued on the promotion and advertisement of prescription-only medicines including GLP-1 receptor agonists and similar drugs for obesity and metabolic disorders, under the Drugs and Cosmetics Act 1940 and Drugs Rules 1945. The committee asked state and union territory drug controllers to keep a vigil on compliance with approved indications, labelling, ethical marketing and risk-management plan obligations and on the exploitation of vulnerable populations; agreed that enforcement action for significant violations sits with the states under intimation to CDSCO; and asked the Indian Pharmacopoeia Commission to compile a monthly or bi-monthly review of adverse events for these medicines. The minutes carry the meeting date as 20 March 2026 while the published file is dated 2 April 2026; the advisory itself has not been published as a standalone PDF on the CDSCO site at the time of writing, so this committee record is the primary evidence of its contents. source
  25. Press Information Bureau, Government of India. GLP-1 drugs: use, risks and regulation, 1 April 2026. Government explainer recording that in India these medicines may be prescribed only by endocrinologists, internal medicine specialists and cardiologists and cannot be bought over the counter; that the DCGI with state drug controllers has intensified surveillance, with 49 entities including online pharmacy warehouses, wholesalers, retailers and slimming or wellness clinics inspected as of 24 March 2026; and that non-compliance can bring licence cancellation, fines and legal action. A further CDSCO advisory dated 27 March 2026 asked all state and union territory drug controllers to strengthen monitoring across the supply chain. source
  26. CDSCO asks states and union territories to monitor surrogate promotion for GLP-1 drugs. Business Standard, 19 May 2026. Reports the direction to state and UT drug controllers to actively monitor print, electronic, digital, social and outdoor media for surrogate promotion, with action available under the Drugs and Magic Remedies (Objectionable Advertisements) Act 1954. Also the source for injectable GLP-1 sales rising 218% on a moving annual turnover basis to ₹1,736 crore in April 2026 from ₹545 crore in April 2025. Sales-audit figures come from commercial tracking rather than an official register. The same report describes Ozempic as approved in India for type 2 diabetes only; note that its statement about tirzepatide conflicts with the manufacturer's own launch materials, which is why indication status here is taken from product sources. source
  27. Cipla Limited. Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes. Press release, 10 December 2025; and Lilly and Cipla sign a distribution and promotion agreement for Yurpeak, 23 October 2025. Yurpeak is a second Lilly tirzepatide brand in India, manufactured and supplied by Lilly, distributed and promoted by Cipla, priced the same as Mounjaro, in six KwikPen strengths from 2.5 to 15 mg. The company materials state tirzepatide is indicated in India as an adjunct to diet and exercise for type 2 diabetes and for chronic weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity. Company communications about their own product; the approved indication of any individual product should be confirmed from its own prescribing information. source
  28. Dr Reddy's Laboratories. Launch of DCGI-approved semaglutide injection Obeda for type 2 diabetes, 21 March 2026. India's first DCGI-approved generic semaglutide, launched with a type 2 diabetes indication, supported by a head-to-head phase III trial in 312 participants showing non-inferior glycaemic reduction and a comparable safety and immunogenicity profile to the originator. Contemporary market coverage described weight-management label expansion as pending at launch. A company communication about its own product. source
  29. Torrent Pharmaceuticals. Launch of semaglutide brands Sembolic and Semalix in India. Press release, 21 March 2026. Torrent launched an injectable (Sembolic, co-marketed with Zydus) and an oral tablet (Semalix) the day after patent expiry, described as the first Indian company to offer generic semaglutide in both formulations, with the injectable starting at ₹3,999 a month. A company communication about its own product; Semalix is a generic equivalent of the originator oral tablet in 3, 7 and 14 mg strengths. source
  30. Factbox: Indian drugmakers flood market with cheaper versions of Novo's Ozempic and Wegovy. Reuters, March 2026. Semaglutide's core Indian patents expired on 20 March 2026. Pre-expiry reporting described more than 40 companies preparing more than 50 brands, with launches beginning within days at up to 70% below originator prices. Prepared or planned brands are not the same as commercially active ones: mid-2026 market trackers counted dozens actually launched rather than the full fifty. Prices and brand counts in a newly opened generic market move quickly and vary by source. source
  31. Foundayo (orforglipron) US FDA approval record, first approved 1 April 2026; and the December 2025 US approval of an oral semaglutide tablet for weight management. Orforglipron is the first once-daily small-molecule oral GLP-1 receptor agonist approved for chronic weight management, and unlike oral semaglutide it carries no food or water timing restriction. Both are United States regulatory actions. Neither product is licensed in India as of August 2026, and approval elsewhere implies neither availability nor approval here. source

This article is for general information and is written for readers in India. It is not a substitute for individual medical advice, diagnosis or prescription. GLP-1 receptor agonists are Schedule H prescription medicines and should be started, adjusted and stopped only under a registered medical practitioner who has assessed your history, examination and baseline tests. Approved indications, prices and product labelling in India have changed repeatedly through 2026; confirm the current status of the specific brand you are prescribed. If you develop any of the urgent symptoms described above, seek care immediately. Report an error on this page.